@article {Carlsenp4036, author = {Kai-H{\r a}kon Carlsen and Leif Bjermer and Barbro Dahl{\'e}n and Tommy Ekstr{\"o}m and Gunilla Hedlin and Trine Stensrud and Leif J{\"o}rgensen and Kjell Larsson}, title = {Exercise test with dry air inhalation compared to mannitol test as marker of exercise induced asthma}, volume = {38}, number = {Suppl 55}, elocation-id = {p4036}, year = {2011}, publisher = {European Respiratory Society}, abstract = {Objective: To compare exercise test with dry air inhalation and mannitol test to discriminate between different asthma treatments.Methods: Exercise test with dry air inhalation (EIA test) (Aiolos bronchial challenge{\textregistered}, Sweden) was compared to inhaled mannitol test in a randomized trial (NCT 00989833) on budesonide/formoterol (B/F) as needed (n=23), budesonide (B; n=21) once daily, terbutaline (T) as needed (n=22) on exercise induced asthma (EIA) in mild asthmatic adults and adolescents. EIA test: 6 minutes treadmill run at 90\% of max aerobic capacity; FEV1 measured before, and 0, 5, 10, 15, 30, 45 minutes after exercise. EIA test was positive with max fall in FEV1 >= 10\% of baseline. Dry powder mannitol was inhaled in cumulative doses from 5 - 635 mg, to find the dose causing 15\% FEV1 fall (PD15). EIA test was performed at trial start, after 3 and 6 weeks, mannitol test at trial start and after 6 weeks.Results: Mean max FEV1 fall after EIA test was 16.34\% at baseline and 13.11\% after 6 weeks treatment. There was a significant improvement in B/F (ΔFEV1: LS mean (95\% CI) -5.4 (-8.93, -1.83) and B (-6.6 (-10.3, -2.96)) groups after 6 weeks, but not in the T group (+1.48 (-2.1, 5.09)). The mannitol test was positive (PD15\<635 mg) in only 31/66 subjects at start, and in 22 at 6 weeks. All 66 subjects had a positive EIA test.Conclusion: All patients had positive EIA test at baseline. The response to the EIA test improved significantly in two of the treatment groups (B/F and B) and discriminated between the treatments. The mannitol test was positive in less than 50\% of the subjects, and could not be used as outcome in the present study.The study was sponsored by AstraZeneca.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/38/Suppl_55/p4036}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }